EDUCATIONAL PRIMER: A New Wave of Systemic Treatments: Atopic Dermatitis, Meet JAK

The increasing incidence of atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. Timely and adequate treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions. However, the treatment of AD is a clinical challenge. Although in many patients AD symptoms can be controlled primarily with topical agents, long-term treatment can be challenging or may not be adequately addressed. Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-term control. In particular, Janus kinase (JAK) inhibitors have emerged as a novel mechanism of action for treatment of AD with one agent that is FDA approved and several others in advanced clinical development. Thus, additional education about current and emerging long-term strategies to AD management is crucial for their interpretation and application to clinical practice.

The live webinar component of the program is designed to provide guidance to clinicians who are in need of additional training to understand these new mechanisms of action and appropriate prescribing methods for emerging immunomodulatory therapies. But first, clinicians would benefit from this educational primer in which they can review fundamental information surrounding AD, including disease pathogenesis, diagnostic criteria, and current non-targeted treatment options.

Target Audience

This activity is designed for an audience of U.S. based dermatologists and allergists, physicians assistants, pharmacists and nurses who are in the care and treatment of patients with moderate-to-severe atopic dermatitis.

Learning Objectives

  • Interpret the efficacy and safety of current non-pharmacological and pharmacological treatments for AD and their limitations in long-term disease management. 
  • Summarize the mechanisms of action and evidence with new and emerging targeted immunomodulatory agents for long-term AD management
  • Develop individualized treatment plans for patients with moderate-to-severe AD that go beyond just treating flares and symptoms in order to optimize long-term control and overall quality of life.
  • Apply best practice for vaccination of immunocompromised AD patients
Course summary
Available credit: 
  • 0.25 AAPA Category I CME
  • 0.25 ACPE Pharmacy
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC
  • 0.25 Participation
Course opens: 
12/23/2021
Course expires: 
12/23/2022
Rating: 
0
  • Atopic dermatitis pathogenesis
  • Key cytokines and signaling pathways
  • Diagnostic criteria
  • Current pharmacologic and non-pharmacologic treatment

AAD 2020: Investigational JAK-1 Inhibitor Abrocitinib A Promising Oral  Therapy for Atopic Dermatitis | PracticeUpdate

Melinda J. Gooderham , MD

Dermatologist

Peterborough, Ontario

 

Brett A. King, MD, PhD

Dermatologist

Middlebury, Connecticut

 

Kim Papp, MD, PhD, FRCPC

Dermatologist

Waterloo, Ontario

 

 

Disclosure of Conflicts of Interest

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
 

Name of Faculty or Presenter

Reported Financial Relationship

Melinda Gooderham, MD

Advisor - AbbVie Inc., Actelion Pharmaceuticals, AMGEN, Arena Pharmaceuticals, Asana Bio Sciences, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Dermavant , Eli Lilly and Company, Galderma SA., Janssen Inc., LEO Pharma, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Sun Pharmaceuticals and UCB.


Consultant - AbbVie Inc., Akros Pharma Inc., AMGEN, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Dermavant , Eli Lilly and Company, Janssen Inc., Kyowa Kirin, Novartis Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceuticals and UCB.


Contracted Research - AbbVie Inc., Akros Pharma Inc., AMGEN, Arcutis Pharmaceuticals Inc., Bausch Health, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Coherus Biosciences, Dermavant , Dermira Inc., Eli Lilly and Company, Galderma SA., GlaxoSmithKline, Glenmark, Janssen Inc., Kyowa Kirin, LEO Pharma, MedImmune, Merck and Co., Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Laboratories, Sanofi Genzyme, Sun Pharmaceuticals, Takeda Pharmaceuticals and UCB.


Speaker - AbbVie Inc., Actelion Pharmaceuticals, AMGEN, Bausch Health, Boehringer Ingelheim International GmbH, Celgene Corporation, Dermavant , Eli Lilly and Company, Galderma SA., Glenmark, Kyowa Kirin, LEO Pharma, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Sun Pharmaceuticals and UCB.

Brett King, MD

Advisory Board: AbbVie, AltruBio, Inc., Almirall, Arena Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Incyte Corp, Ostuska/Visterra Inc., Pfizer Inc., Regeneron, Sanofi Genzyme and Viela Bio

Consultant: AbbVie, AltruBio Inc., Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Myers Squibb, Concert Pharmaceuticals, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc., Pfizer Inc., Regeneron, Sanofi Genzyme, TWi Biotechnology Inc.

Speaker: Pfizer Inc., Regeneron and Sanofi Genzyme

Kim Papp, MD, PhD, FRCPC

Advisory Boards: AbbVie, Amgen, Astellas, Bausch Health/Valeant, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dice Pharmaceuticals, Dow Pharma, Galderma, Janssen, Merck (MSD), Novartis, PRCL Research, Regeneron, Sanofi-Aventis/Genzyme, Sun Pharma, UCB

Consultant: AbbVie, Akros, Amgen, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Celitrion, Coherus, Dermava, Dermira, Dire Pharmaceuticals, Dow Pharma, Eli Lilly, Evelo, Forbion, Galapagos, Galderma, Genentech, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Reistone, Roche, Sanofi-Aventis/Genzyme, Sandoz, Takeda, UCB, vTv Therapeutics, Xencor

Clinical Research Grants: AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GKS, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Merck (MSD), Merck-Serono, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sub Pharma, Takeda, UCB

Scientific Officer: Akros, Anacor, Arcutis, Dice Pharmaceuticals, Kyowa Hakko Kirin

Speakers Bureau: AbbVie, Amgen, Astellas, Baush Health/Valeant, Can-Fite Biophrama, Eli Lilly, Galderma, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Merck (MSD), Novartis, Pfizer, Sanofi-Aventis/Genzyme

Steering Committee: AbbVie, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa Hakko Kirin, Merck (MSD), Merck-Serono, Novartis, Pfizer, PRCL Research, Sanofi-Aventis/Genzyme

 

 

Dorothy Caputo, MA, BSN, RN - AKH CE Director of Accreditations, has nothing to disclose.
Dorothy A. Duffy, RPh - AKH Pharmacy Reviewer, has nothing to disclose.

AKH Planners and Reviewers have no relationships to disclose.

The content manager, Amy Kousouros, from LivDerm, has nothing to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Jointly provided by the AKH Inc., Advancing Knowledge in Healthcare and LivDerm.

Estimated time to complete activity: 15 minutes

Commercial Support

This activity is supported by educational grants from Incyte and Pfizer.

Physician Continuing Medical Education

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant Continuing Medical Education

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until {December 21, 2022}. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Education

Nurse

0.25 ANCC contact hours

Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 0.25 contact hours.

 

Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.

Hardware/Software Requirements
A computer or device with an internet connection.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

 

 

 

 

Available Credit

  • 0.25 AAPA Category I CME
  • 0.25 ACPE Pharmacy
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC
  • 0.25 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.